A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Trial Profile

A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Azacitidine (Primary) ; Decitabine (Primary) ; Crisantaspase; Crisantaspase; Cytarabine; Cytarabine; Daunorubicin; Dexrazoxane; Etoposide; Filgrastim; Fludarabine; Idarubicin; Mitoxantrone; Sorafenib
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 18 Oct 2017 Planned End Date changed from 30 Jun 2027 to 1 Jun 2027.
    • 18 Oct 2017 Planned primary completion date changed from 30 Jun 2025 to 1 Jun 2025.
    • 26 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top